 |
|
|
|
 |
|
|
| Article 1 to 10 out of 20 concerning DxS Ltd
|
-
QIAGEN Acquires Exclusive Licence for Key PI3K gene
(10 Feb 2010)
Patent licensed from Johns Hopkins University for PCR-based companion diagnostics for cancer treatments
QIAGEN announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays. Research has shown that variation in the PI3K ...
-
QIAGEN Unit And Pfizer Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients
(05 Feb 2010)
Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of ...
-
QIAGEN Acquires DxS Ltd
(24 Sep 2009)
QIAGEN N.V. announced that it has acquired DxS Ltd (DxS), a privately-held developer and manufacturer of companion diagnostic products headquartered in Manchester, United Kingdom. The transaction is valued at approximately US$ 95 million in cash ...
-
DxS Enters Into Collaboration With Bristol-Myers Squibb And ImClone Systems To Provide a K-RAS Companion Diagnostic For ERBITUX
(04 Sep 2009)
DxS has entered into a collaboration agreement with Bristol-Myers Squibb Company and ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to further develop a K-RAS companion diagnostic for ERBITUX® (cetuximab) in the United States ...
-
DxS Appoints David Jackson as Vice President of Business Development and Licensing
(18 Aug 2009)
DxS Ltd has announced the appointment of Dr. David Jackson as Vice President of Business Development and Licensing. Dr. Jackson will be responsible for planning and executing business development efforts for the companion diagnostics and technology ...
-
DxS Appointments Dave Clennell as Director of Quality
(11 Aug 2009)
DxS Ltd has announced the appointment of Dave Clennell as Director of Quality. Dave has worked in Quality within the healthcare industry for 30 years and has a wealth of experience in FDA-related markets. Prior to joining DxS, Dave worked as ...
-
DxS and Epigenomics Cross-License Technology for In Vitro Diagnostics
(21 Jul 2009)
DxS Ltd. and Epigenomics AG announced that they have cross-licensed certain technologies enabling both companies to develop and commercialise in vitro diagnostic (IVD) products based on DNA methylation that utilise DxS' proprietary Scorpions ...
-
Exosome Diagnostics and DxS Collaborate to Develop Blood Based Tests for Key Cancer Mutations
(23 Jun 2009)
Exosome Diagnostics, Inc. and DxS Ltd. announced that they will collaborate on the development of blood based companion diagnostics for key cancer gene mutations, such as KRAS, BRAF and EGFR. The collaboration will use DxS’ Scorpions® real-time PCR ...
-
DxS appoints Ron Long as Chairman as part of Continued Growth and Expansion Strategy
(11 Jun 2009)
DxS Ltd has announced the appointment of Ron Long as the company Chairman. Ron has a wealth of experience in both public and private companies stretching over 40 years, with an impressive record of leadership in a number of companies, including ...
-
Boehringer Ingelheim and DxS sign an agreement for companion diagnostic to identify EGFR mutations in patients with lung cancer
(03 Jun 2009)
DxS and Boehringer Ingelheim have entered into an agreement to provide a companion diagnostic test kit for Boehringer Ingelheim’s compound BIBW 2992 (Tovok™) to identify mutations of the EGFR (epidermal growth factor receptor) in patients with non ...
Additional information
DxS Ltd
Manchester, United Kingdom
Company
|
|
|
|
|
|
Top
